BioCardia, CellProThera deal

Early next year, CellProThera and BioCardia will conduct the Phase I/IIb EXCELLENT trial evaluating CellProThera's Protheracytes CD34+ cells delivered by BioCardia's Helix Transendocardial delivery system. The trial will enroll 44 patients in the U.K. and France with an acute myocardial infarction (AMI) and a left ventricle ejection fraction remaining below or equal to 45% after percutaneous transluminal coronary angioplasty and stent implantation. Under the deal, BioCardia is eligible for milestones related to a future clinical development program, and CellProThera is eligible for milestones related to timely completion of the trial. The partners declined to disclose financial details. ...